SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.

MLA

Mesa, Ruben A., et al. “SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 35, no. 34, Dec. 2017, pp. 3844–50. EBSCOhost, https://doi.org/10.1200/JCO.2017.73.4418.

APA

Mesa, R. A., Kiladjian, J.-J., Catalano, J. V., Devos, T., Egyed, M., Hellmann, A., McLornan, D., Shimoda, K., Winton, E. F., Deng, W., Dubowy, R. L., Maltzman, J. D., Cervantes, F., & Gotlib, J. (2017). SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 35(34), 3844–3850. https://doi.org/10.1200/JCO.2017.73.4418

Chicago

Mesa, Ruben A, Jean-Jacques Kiladjian, John V Catalano, Timothy Devos, Miklos Egyed, Andrzei Hellmann, Donal McLornan, et al. 2017. “SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 35 (34): 3844–50. doi:10.1200/JCO.2017.73.4418.